galinpepimut-s
Vaccineexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03761914)
Timeline
Indications
Studied for
- Colorectal Neoplasms · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 3
- Lymphoma, Non-Hodgkin · Phase 1
- Mesothelioma · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Wilms Tumor · Phase 1
Mechanism of action
- Wilms tumor proteinVACCINE ANTIGEN
Wilms tumor protein vaccine antigen
- Wilms tumor proteinImmunity, active
immunity, active - wt1
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833386 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05320809 | Phase 1 | Aug 1, 2022 | 3D Medicines, Peking University |
| NCT04229979 | Phase 3 | Jan 31, 2020 | Sellas Life Sciences Group |
| NCT04040231 | Phase 1 | Jul 24, 2019 | Memorial Sloan-Kettering Cancer Center |
| NCT03761914 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Cancer Insight, LLC, Merck, Sellas Life Sciences Group |
| NCT05593185 | N/A | — | Sellas Life Sciences Group |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sellas Life Sciences Group | For profit | 3 | 3 | 3 | 2019 |
| 3D Medicines | For profit | 1 | 1 | 1 | 2022 |
| Cancer Insight, LLC | For profit | 1 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1